62 completed, 30 recruiting, 20 unknown, 12 terminated. 49 Phase 2, 25 Phase 1, 16 Phase 3, 13 Not applicable, 3 Early Phase 1.
Follow Cholangitis, Sclerosing: new trials by email Literature Review of Cholangitis, Sclerosing trials Research Report on Cholangitis, Sclerosing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease | Phase 2 | Not yet recruiting | Mayo Clinic | 15 | 2026-11-01 | 2026-09-28 |
| Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis Oral Vancomycin - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | Tampere University Hospital | 140 | 2026-10-01 | 2026-09-10 |
| LEOPARD Prospective Validation Cohort 1 Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking - Decompensated Liver Cirrhosis, Primary Biliary Cholangitis | Recruiting | Assistance Publique - Hôpitaux de Paris | 630 | 2026-07-07 | 2026-07-29 | |
| Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Placebo (blinded), Vancomycin (blinded), Vancomycin (open-label extension) - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Recruiting | McMaster University | 14 | 2026-06-17 | 2026-10-09 |
| The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching Upadacitinib 15 MG - Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | RenJi Hospital | 44 | 2026-06-01 | 2026-07-01 |
| A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis Elafibranor, Placebo - Primary Sclerosing Cholangitis | Phase 3 | Recruiting | Ipsen | 350 | 2026-05-14 | 2026-10-01 |
| Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation Fecal microbiota transplantation (FMT), Sham-transplantation (placebo) - Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 72 | 2026-05-01 | 2026-03-17 |
| Biodegradable Stents in Primary Sclerosing Cholangitis archimedes stent - Primary Sclerosing Cholangitis (PSC) | Not applicable | Recruiting | King's College Hospital NHS Trust | 20 | 2026-03-01 | 2026-05-29 |
| A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) TAK-781, Placebo - Healthy Volunteers, Primary Sclerosing Cholangitis | Phase 1 | Recruiting | Takeda | 134 | 2026-01-07 | 2026-03-05 |
| A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC LB-P8 low-dose, LB-P8 high-dose, Placebo - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Recruiting | LISCure Biosciences | 87 | 2025-11-01 | 2025-10-24 |
| Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis HK-660S 100mg, HK-660S 200mg, Placebo - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | CuromeBiosciences | 105 | 2025-08-18 | 2025-05-16 |
| A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis Aramchol meglumine - Primary Sclerosing Cholangitis | Phase 2 | Withdrawn | Galmed Pharmaceuticals Ltd | 2025-06-01 | 2025-06-12 | |
| Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) - Primary Sclerosing Cholangitis, Liver Transplant, Complications | Phase 2 | Recruiting | Mayo Clinic | 80 | 2025-04-15 | 2026-07-17 |
| Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) norucholic acid - Primary Sclerosing Cholangitis | Phase 3 | Not yet recruiting | Dr. Falk Pharma GmbH | 120 | 2025-03-01 | 2025-03-20 |
| A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions Liver Cirrhosis, Hepatocellular Carcinoma (HCC) | Recruiting | Imperial College London | 750 | 2025-02-13 | 2025-03-07 | |
| LEOPARD Training and Validation Data Collection Study Decompensated Liver Cirrhosis, Primary Biliary Cholangitis | Recruiting | Assistance Publique - Hôpitaux de Paris | 4500 | 2025-02-04 | 2026-07-29 | |
| Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography Endoscopic retrograde cholangiopancreatography (ERCP) - Choledocholithiasis, Choledocholithiasis With Acute Cholangitis | Not yet recruiting | Germans Trias i Pujol Hospital | 3000 | 2024-11-01 | 2024-11-01 | |
| A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. aldafermin, Placebo - Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Withdrawn | NGM Biopharmaceuticals, Inc | 2024-10-21 | 2025-05-07 | |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) Maralixibat, Placebo - Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Phase 3 | Active not recruiting | Mirum Pharmaceuticals, Inc. | 90 | 2024-10-14 | 2026-10-06 |
| A Study of SIPLIZUMAB in AILD and LT Patients Siplizumab - Autoimmune Liver Disease, Liver Transplant Disorder | Phase 1 | Recruiting | Elizabeth C. Verna | 8 | 2024-09-11 | 2025-11-24 |
Showing 20 of 146. Sign in to see all of them.
Liver Cirrhosis, Biliary (19) · Inflammatory Bowel Diseases (16) · Hepatitis, Autoimmune (15) · Cholangiocarcinoma (10) · Cholestasis (8) · Colitis, Ulcerative (8) · Liver Diseases (7) · Pruritus (7) · Cholangitis (6) · Digestive System Diseases (6) · Fibrosis (5) · Non-alcoholic Fatty Liver Disease (5) · Bile Duct Diseases (4) · Biliary Atresia (4)
Bile Duct Diseases (142) · Biliary Tract Diseases (142) · Cholangitis (140) · Digestive System Diseases (140) · Pathological Conditions, Signs and Symptoms (33) · Liver Diseases (28) · Pathologic Processes (27) · Gastroenteritis (24) · Gastrointestinal Diseases (23) · Intestinal Diseases (22) · Fibrosis (20) · Cholestasis, Intrahepatic (19) · Liver Cirrhosis (19) · Immune System Diseases (16) · Cholestasis (15)
Vancomycin (13) · cilofexor (4) · Ursodeoxycholic Acid (3) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (2) · Bezafibrate (2) · Fecal Microbiota Transplantation (2) · Fenofibrate (2) · Metronidazole (2) · Multiparametric Magnetic Resonance Imaging (2) · Tretinoin (2) · aldafermin (2) · streptococcal polysaccharide type III group B (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · 24-norursodeoxycholic acid (1) · Amoxicillin (1)
Mayo Clinic (13) · Gilead Sciences (7) · Assistance Publique - Hôpitaux de Paris (6) · Brigham and Women's Hospital (4) · Stanford University (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (3) · Children's Hospital Medical Center, Cincinnati (3) · Dr. Falk Pharma GmbH (3) · HighTide Therapeutics (Hong Kong) Limited (3) · Karolinska University Hospital (3) · Mirum Pharmaceuticals, Inc. (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Perspectum (3) · University of Birmingham (3) · Beth Israel Deaconess Medical Center (2)
United States (74) · United Kingdom (21) · Canada (19) · France (17) · Italy (14) · Germany (13) · Netherlands (13) · Spain (12) · Belgium (10) · Sweden (9) · Austria (7) · Israel (7) · China (6) · Australia (5) · Denmark (5)
Alexander Miethke, MD (2) · Elizabeth Carey, MD (2) · Joshua Korzenik, MD (2) · Michael Trauner, MD (2) · Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Alastair Smith, MD (1) · Amy E Taylor, MD (1) · Andrea Tringali, MD, PhD (1) · Andrew Muir, MD (1) · Annika Bergquist, Assoc prof (1) · Annika Bergquist, MD PhD (1) · Annika Bergquist, PhD (1)
PMID 23054338, PMID 32633158, PMID 41804276, PMID 10655252, PMID 19585548, PMID 21134112, PMID 21791473, PMID 21885599, PMID 23384404, PMID 24206748, PMID 24914504, PMID 25826274, PMID 26048252, PMID 28249726, PMID 28529147, PMID 28535810, PMID 28674140, PMID 29803836, PMID 30153359, PMID 30472651, PMID 30661255, PMID 31611594, PMID 32165251, PMID 33031833, PMID 33681680, PMID 33798541, PMID 33898959, PMID 35080454, PMID 35638103, PMID 36327436, PMID 36520162, PMID 37055910, PMID 37184523, PMID 38630086, PMID 38967589, PMID 38976363, PMID 38977324, PMID 39424872, PMID 39601354, PMID 39673746, PMID 39762111, PMID 39880819, PMID 39996122, PMID 40350321, PMID 40671462, PMID 41016442, PMID 41173015, PMID 41513411, PMID 42271063, PMID 42489629
2014 (4), 2019 (2), 2023 (2), 2015 (1), 2016 (1), 2018 (1), 2025 (1), R01DK056924 (1), R03DK052344 (1), R03DK071851 (1), RC2DK118619 (1), U24DK062456 (1)